GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Capex-to-Revenue

CG Oncology (CG Oncology) Capex-to-Revenue : 0.02 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

CG Oncology's Capital Expenditure for the three months ended in Mar. 2024 was $-0.01 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.53 Mil.

Hence, CG Oncology's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.02.


CG Oncology Capex-to-Revenue Historical Data

The historical data trend for CG Oncology's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Capex-to-Revenue Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Revenue
0.01 0.07 -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial - - - - 0.02

Competitive Comparison of CG Oncology's Capex-to-Revenue

For the Biotechnology subindustry, CG Oncology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where CG Oncology's Capex-to-Revenue falls into.



CG Oncology Capex-to-Revenue Calculation

CG Oncology's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.204
=0.00

CG Oncology's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.012) / 0.529
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology  (NAS:CGON) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


CG Oncology Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of CG Oncology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology (CG Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines